Hearing Disorders is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hearing Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hearing Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hearing Disorders overview

Hearing loss is an extremely common medical condition, ranging from neonates to the elderly, progressing in incidence and severity with age; about one-third of older adults have hearing loss. Diagnosis and management require an interprofessional team that includes the general practitioner, otolaryngologist, speech therapist, audiologist, and social worker. To correctly address hearing loss, understanding the nature of hearing loss and the equipment that is needed to improve auditory reception is crucial. In terms of children’s hearing loss, pediatricians need to be integrated into their care to ensure normal hearing and language development of the child. Hearing loss is a common problem caused by loud noise, aging, disease, and genetic variations. The three basic categories of hearing loss are sensorineural hearing loss, conductive hearing loss, and mixed hearing loss. Conductive involves the outer or middle ear, sensorineural involves the inner ear, and mixed involves both. Symptoms of hearing loss may include muffling of speech and other sounds, trouble hearing letters of the alphabet that aren’t vowels, and often asking others to speak more slowly, clearly, and loudly.

For a complete picture of PTSR and LoA scores for drugs in Hearing Disorders, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.